SCHEMBL2294935

SCHEMBL2294935

COc1cccc(OCC(N)=O)c1-c1nc2ccccn2c1Nc1c(C)cccc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.52
GAA P10253 8/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
HTT P42858 2/20 0.52
KMT2A Q03164 2/20 0.52
MAPK1 P28482 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
TP53 P04637 5/20 0.48
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
PKM P14618 2/20 0.43
PKLR P30613 1/20 0.43
THRB P10828 1/20 0.42
TUBB4A P04350 4/20 0.41
TUBB P07437 4/20 0.41
TUBA3C P0DPH7 4/20 0.41
TUBA1B P68363 4/20 0.41
TUBA4A P68366 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2291876 0.95 MAPT (0.47) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL2293580 0.94 GAA (0.55) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL2292734 0.94 GAA (0.46) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL2287179 0.91 GAA (0.50) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL2287264 0.91 GAA (0.52) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL2292450 0.91 GAA (0.52) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL2292071 0.90 SMN1; SMN2 (0.41) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL2294341 0.90 GAA (0.40) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL2289156 0.90 GAA (0.51) MAPTGAASMN1; SMN2HTTKMT2A
SCHEMBL2296059 0.90 MAPT (0.51) MAPTGAASMN1; SMN2HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US claimed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 MAPT 1138/4885GAA 1202/4885SMN1; SMN2 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.